<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="for its progenitor. Women and children are less susceptible to" exact="SARS-CoV-2 infection," post="while the elderly and people with comorbidities are more"/>
 <result pre="(84,507; 4645) [5]. Notably, all age groups show susceptibility to" exact="SARS-CoV-2 infection," post="from newborns to the elderly [6]. The average age"/>
 <result pre="newborns to the elderly [6]. The average age noted for" exact="SARS-CoV-2 infection" post="susceptibility is 55.5 years, while that for the case"/>
 <result pre="mutations in civet CoVs prior to its spillover. Similarly, the" exact="Middle East respiratory syndrome" post="(MERS)-CoV also circulated and acquired mutations in camels for"/>
 <result pre="syndrome (SARS) and MERS. 2.1. SARS-CoV The first incidence of" exact="SARS-CoV infection" post="was reported on 16 November 2002, in the coastal"/>
 <result pre="of virus transmission [19,23]. 2.3. SARS-CoV-2 The first case of" exact="SARS-CoV-2 infection" post="was reported in the first week of December 2019"/>
 <result pre="pregnancy stage [55]. 7.2. Incubation Period The incubation period for" exact="SARS-CoV-2 infection" post="ranged from 2 to 14 days in human-to-human transmission,"/>
 <result pre="Population Susceptibility There is no age limit for vulnerability to" exact="SARS-CoV-2 infection." post="However, cases with higher morbidity and chances of mortality"/>
 <result pre="susceptible to the infection [25]. Women are less susceptible to" exact="SARS-CoV-2 infection" post="than men and this is possibly due to different"/>
 <result pre="less virus load and inflammation. Recently, studies have shown that" exact="SARS-CoV-2 infection" post="in children (though less severely affected), may develop the"/>
 <result pre="not clear whether Kawasaki disease-like forms are a result of" exact="SARS-CoV-2 infection" post="alone or just SARS-CoV-2 induced aggravations in Kawasaki disease"/>
 <result pre="9.2. Immunopathobiology Existing literature documents that patients suffering from severe" exact="SARS-CoV-2 infection" post="might suffer from the cytokine storm syndrome that could"/>
 <result pre="occur at a similar point or slightly earlier than in" exact="SARS-CoV infection" post="[86,87]. A recently released antibody profile against SARS-CoV-2 has"/>
 <result pre="responses against SARS-CoV-2. Increasing evidence suggests that fatalities resulting from" exact="SARS-CoV-2 infection" post="could be primarily attributed to the ARDS [90,91], which"/>
 <result pre="IP10, MCP1, MIP1Î±, and TNF) from immune effector cells during" exact="SARS-CoV-2 infection" post="[91,93,94,95,96,97,98]. In this context, the increased levels of IL-6"/>
 <result pre="different animals has recently been evaluated through an experiment on" exact="SARS-CoV-2 infection," post="where SARS-CoV-2 was found to replicate efficiently in cats"/>
 <result pre="an ongoing search for a suitable animal model to study" exact="SARS-CoV-2 infection" post="[104]. After the SARS outbreak, numerous inbred mouse strains"/>
 <result pre="being made globally to develop safe and effective vaccines against" exact="SARS-CoV-2 infection" post="[120]. Approximately 200 vaccine candidates have already been developed"/>
 <result pre="of China in February 2020, is commonly used to treat" exact="influenza infection" post="in China and Japan and has shown promising results"/>
 <result pre="and has shown promising results in shortening the course of" exact="SARS-CoV-2 infection" post="[12,124,125]. This drug acts by inhibiting the RNA-dependent RNA"/>
 <result pre="repurposed drug that was initially developed for the treatment of" exact="Ebola" post="virus infection. Remdisivir is reported to prevent viral replication"/>
 <result pre="readily available therapies may prove beneficial in patients with severe" exact="SARS-CoV-2 infection." post="A humanized monoclonal antibody, viz. tocilizumab, competitively binds to"/>
 <result pre="Assoc.20203231313131410.1001/jama.2020.2131 7.ChenN.ZhouM.DongX.QuJ.GongF.HanY.QiuY.WangJ.LiuY.WeiY.et al.Epidemiological and clinical characteristics of 99 cases of" exact="2019 novel coronavirus pneumonia" post="in Wuhan, China: A descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 8.WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.WangB.XiangH.ChengZ.XiongY.et al.Clinical characteristics"/>
 <result pre="Engl. J. Med.20203821199120710.1056/NEJMoa200131631995857 12.GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.TanK.S.WangD.Y.YanY.The origin, transmission and clinical therapies on" exact="coronavirus disease 2019" post="(COVID-19) outbreakâ€&quot;An update on the statusMil. Med. Res.202071110.1186/s40779-020-00240-032169119 13.HodgsonJ.The"/>
 <result pre="20.CormanV.M.AlbarrakA.M.OmraniA.S.AlbarrakM.M.FarahM.E.AlmasriM.MuthD.SiebergA.MeyerB.AssiriA.M.et al.Viral shedding and antibody response in 37 patients with" exact="Middle East respiratory syndrome" post="coronavirus infectionClin. Infect. Dis.20166247748310.1093/cid/civ95126565003 21.SuS.WongG.ShiW.LiuJ.LaiA.C.ZhouJ.LiuW.BiY.GaoG.F.Epidemiology, genetic recombination, and pathogenesis"/>
 <result pre="as compared with SARS-CoV-1N. Engl. J. Med.20203821564156710.1056/NEJMc200497332182409 47.Van DoremalenN.BushmakerT.MunsterV.Stability of" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) under different environmental conditionsEurosurveillance2013182059010.2807/1560-7917.ES2013.18.38.2059024084338 48.SizunJ.YuM.TalbotP.Survival of human"/>
 <result pre="Assoc.20203231406140710.1001/jama.2020.2565 58.HindsonJ.COVID-19: Faecalâ€&quot;oral transmission?Nat. Rev. Gastroenterol. Hepatol.20201725910.1038/s41575-020-0295-732214231 59.XuY.LiX.ZhuB.LiangH.FangC.GongY.GuoQ.SunX.ZhaoD.ShenJ.Characteristics of pediatric" exact="SARS-CoV-2 infection" post="and potential evidence for persistent fecal viral sheddingNat. Med.20202650250510.1038/s41591-020-0817-432284613"/>
 <result pre="clinical application of a rapid IGM-IGG combined antibody test for" exact="SARS-CoV-2 infection" post="diagnosisJ. Med. Virol.202010.1002/jmv.2572732104917 114.ZhengJ.SARS-CoV-2: An emerging coronavirus that causes"/>
 <result pre="in designing and developing vaccines, drugs, and therapies to counter" exact="Ebola" post="virusFront. Immunol.20189180310.3389/fimmu.2018.0180330147687 153.ChatterjeeP.NagiN.AgarwalA.DasB.BanerjeeS.SarkarS.GuptaN.GangakhedkarR.R.The 2019 novel coronavirus disease (COVID-19) pandemic:"/>
 <result pre="USA Clinical trials are under progress Developed for treatment of" exact="Ebola" post="virus infection Lopinavir + Ritonavir AbbVie, USA Further research"/>
</results>
